Analytik Jena to develop products for sepsis diagnostics

All assets taken over from insolvent company SIRS-Lab GmbH

08-May-2013 - Germany

Analytik Jena has acquired all of the assets of the insolvent company SIRS-Lab GmbH as part of an asset deal. SIRS-Lab, a company that develops molecular diagnostics methods and testing systems for life-threatening infections like sepsis, had filed for insolvency in December 2012. Analytik Jena AG, which as part of the acquisition will also take on the entire range of product expertise, including more than 50 patents and 10 employees at the Jena site, will for the first time be entering the market of sepsis diagnostics, continuing the development work and the expertise of SIRS-Lab in this field.

“In recent years, SIRS-Lab has built up considerable competence in the field of sepsis analytics and has achieved initial successes. The results from a first application study are highly promising. The aim is to identify life-threatening infections quickly and early. In particular, the region around Jena with the University Hospital and various research institutions offers excellent conditions to allow us to be able to serve this large market with products in the future,” says Klaus Berka, CEO of Analytik Jena AG.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances